New drug combo shows promise for tough ovarian cancer
NCT ID NCT02195973
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested whether adding a new drug called LDE225 to standard chemotherapy (paclitaxel) is safe for women with ovarian cancer that no longer responds to platinum-based treatments. Fifteen participants were monitored for side effects and to find the best dose. The goal was to control the disease, not cure it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can heated chemotherapy improve ovarian cancer outcomes?
- Can engineered immune cells target a common ovarian cancer protein?
- Experimental pill takes on Hard-to-Treat ovarian cancer
- New drug cocktail aims to shrink recurrent ovarian tumors
- Targeted drug hunts down cancer cells in advanced bladder cancer trial
- Radiation boost may Re-Sensitize ovarian cancer to PARP inhibitors